PANG — Pangaea Oncology SA Balance Sheet
0.000.00%
- €58.04m
- €58.81m
- €14.27m
- 25
- 16
- 67
- 25
Annual balance sheet for Pangaea Oncology SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Interim Report | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1.04 | 2.93 | 8.51 | 2.79 | 4.43 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3.97 | 4.08 | 4.38 | 6.42 | 7.99 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 5.49 | 7.52 | 13.3 | 9.75 | 13.1 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.553 | 0.429 | 0.353 | 0.545 | 0.901 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 17 | 20.8 | 28.4 | 28.4 | 32.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.68 | 3.18 | 2.72 | 6.86 | 7.01 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 8.72 | 6.76 | 5.49 | 10.5 | 10.3 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 8.24 | 14.1 | 22.9 | 18 | 22.1 |
Total Liabilities & Shareholders' Equity | 17 | 20.8 | 28.4 | 28.4 | 32.4 |
Total Common Shares Outstanding |